Abstract
Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Current Alzheimer Research
Title: IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration
Volume: 7 Issue: 7
Author(s): A. Zambrano, C. Otth, R.B. Maccioni and I.I. Concha
Affiliation:
Keywords: IL-3, neuroprotection, Tau, Tg2576, Aβ, neurodegeneration, cytokines, caspase 3.
Abstract: Interleukin-3 (IL-3) regulates the proliferation, survival and differentiation of haematopoietic cells via interaction with specific cell-surface receptors. IL-3 is expressed in several non-hematopoietic cell types. Studies have demonstrated the presence of IL-3 in the central nervous system, however, its physiological role in these cells is poorly understood. Previously we have been demonstrated that IL-3 prevents neuronal death induced by fibrillary β amyloid in these cells, by PI 3-kinase and Jak/STAT pathway activation. In this study, we demonstrated that IL-3 significantly reduced Aβ- promoted neurite degeneration and toxicity. Thus, this cytokine provides cellular protection against Aβ neurotoxicity in primary cortical neuronal cells, by modulating microtubular dynamics and prevention of tau cleavage and hyperphosphorylation. We also demonstrates that IL-3 is expressed in the “in vivo” mouse model of AD, Tg2576, which also expresses human AβPP with the Swedish mutation. In summary, these results suggest that IL-3 could play a neuroprotective role in AD.
Export Options
About this article
Cite this article as:
Zambrano A., Otth C., Maccioni R.B. and Concha I.I., IL-3 Control Tau Modifications and Protects Cortical Neurons from Neurodegeneration, Current Alzheimer Research 2010; 7 (7) . https://dx.doi.org/10.2174/156720510793499011
DOI https://dx.doi.org/10.2174/156720510793499011 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Juvenile Neuronal Ceroid-Lipofuscinosis (Batten Disease): A Brief Review and Update
Current Molecular Medicine Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Alzheimer´s Disease-associated Aβ42 Peptide: Expression and Purification for NMR Structural Studies
Current Chemical Biology Advancements in Treatment Options of Women Infertility
Current Women`s Health Reviews Models of Infection Before and After Stroke: Investigating New Targets
Infectious Disorders - Drug Targets Epigenetic Regulation of Memory-Therapeutic Potential for Disorders
Current Neuropharmacology Translational Methods for Non-Invasive Electrical Stimulation to Facilitate Gait Rehabilitation Following Stroke - The Future Directions
Neuroscience and Biomedical Engineering (Discontinued) In Silico Screening of Drugs to Find Potential Gamma-Secretase Inhibitors Using Pharmacophore Modeling, QSAR and Molecular Docking Studies
Combinatorial Chemistry & High Throughput Screening Commentary (Complement-Initiated Neuroinflammation and Its Role in Early Stage Alzheimers Disease)
Current Alzheimer Research PET Molecular Imaging of Hypoxia in Ischemic Stroke: An Update
Current Vascular Pharmacology Cigarette Smoking and Angiogenesis: What is the Role of Endothelial Progenitor Cells?
Current Angiogenesis (Discontinued) Quality of Life in Dementia Sufferers: The Role of Diet and Exercise
Current Alzheimer Research The Neuronal Cytoskeleton as a Potential Therapeutical Target in Neurodegenerative Diseases and Schizophrenia
Current Drug Targets - CNS & Neurological Disorders ATP-Binding Cassette Transporters in Inflammatory Brain Disease
Current Pharmaceutical Design Elucidation of Pathophysiology and Treatment of Neuropathic Pain
Central Nervous System Agents in Medicinal Chemistry Combining Neuropsychological and Structural Neuroimaging Indicators of Conversion to Alzheimers Disease in Amnestic Mild Cognitive Impairment
Current Alzheimer Research Neurodegenerative Disorders and Cholesterol
Current Alzheimer Research Treatment of Cardiovascular Risk Factors in Women
Current Medicinal Chemistry Editorial (Thematic Issue: Novel Perspectives for Parkinson’s Disease Therapy: Insights from the Latest Advances in Disease Pathophysiology, Diagnostic and Experimental Tools and Molecular Targets)
CNS & Neurological Disorders - Drug Targets Two Age-Related Accumulation Profiles of Toxic Metals
Current Aging Science